Ignite Creation Date:
2024-05-06 @ 6:09 PM
Last Modification Date:
2024-10-26 @ 2:42 PM
Study NCT ID:
NCT05563246
Status:
COMPLETED
Last Update Posted:
2024-03-28
First Post:
2022-09-28
Brief Title:
A Study of LY3473329 in Adult Participants With Elevated Lipoproteina at High Risk for Cardiovascular Events
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
KRAKEN A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoproteina at High Risk for Cardiovascular Events
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
KRAKEN
Brief Summary:
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lpa at high risk for cardiovascular events
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2O-MC-EKBC | OTHER | Eli Lilly and Company | None |